查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1452935

全球真实世界证据解决方案市场 2024-2031

Global Real-World Evidence Solutions Market 2024-2031
出版日期: | 出版商: Orion Market Research | 英文 200 Pages | 商品交期: 2-3个工作天内

价格

全球现实世界证据解决方案市场预计在预测期内（2024-2031 年）将以 12.40% 的CAGR成长。市场的成长归因于医疗保健行业不断增长的需求，优先考虑以患者为中心的方法，旨在更快、更有效率的临床试验，以加速患者获得创新治疗。例如，2023 年6 月，Verana Health推出了VeraSite，基于订阅的工具，用于识别潜在的临床试验地点。该工具使申办者和 CRO 能够快速识别具有临床专业知识和患者群体的实践，指导地点选择并允许与感兴趣的实践直接联繫。

细分市场前景

全球现实世界证据解决方案市场按组件、应用程式和最终用户细分。根据组成部分，市场细分为服务和资料集。根据应用，市场细分为药物开发和审批、上市后监督、市场准入报销/涵盖最终用户决策以及临床和监管决策。此外，根据最终用户，市场细分为製药和医疗器材公司、医疗保健提供者、医疗保健支付者等。预计製药和医疗器材公司的子类别会占领最终用户细分市场的很大一部分市场份额。这一增长可归因于真实世界证据（RWE）研究的重要性日益增加，这对于药物审批、真实世界性能评估和防止召回、帮助患者利益识别、监管批准、报销和增加使用适应症越来越重要。

肿瘤学子细分市场预计将在全球现实世界证据解决方案市场中占据相当大的份额

在这些应用中，肿瘤学子细分市场预计将在全球现实世界证据解决方案市场中占据相当大的份额。该细分市场的成长归因于癌症研究和治疗中数据驱动决策的日益重视，反映了更广泛的行业趋势。此外，市场参与者正在寻求新产品的推出来满足对解决方案的需求。 。例如，2023 年 5 月，Flatiron Health 扩展到肿瘤学真实世界证据生成领域。其综合现实世界证据 (RWE) 解决方案方法使合作伙伴能够产生强大的 RWE 和见解。它使 Flatiron 成为整个产品生命週期中肿瘤学 RWD/E 开发的“一站式商店”，从而改善癌症患者的体验。

区域展望

全球现实世界证据解决方案市场根据地理位置进一步细分，包括北美（美国和加拿大）、欧洲（英国、义大利、西班牙、德国、法国和欧洲其他地区）、亚太地区（印度、中国、日本、韩国和亚洲其他地区）以及世界其他地区（中东和非洲以及拉丁美洲）。其中，亚太地区预计将在全球市场中占据显着份额，因为该地区老年人口数量不断增加，癌症和慢性病发病率较高，此外，对医疗器械的需求也有所增加。医疗保健服务..

北美地区预计在全球真实世界证据解决方案市场中将以显着的复合CAGR成长

在所有地区中，北美地区预计在预测期内将以相当大的CAGR成长。区域成长归因于高品质现实世界资料来源的不断增加，例如穿戴式装置、医疗保健应用程式和电子健康记录。 。据美国国家卫生研究院 (gov.) 称，2023 年 10 月，该出版物对利用医疗保健领域的真实世界证据 (RWE) 的全球监管环境进行了最新回顾。它评估不同地区框架、指南、资料品质、研究方法和程序指南的可用性。该审查还强调了未来发展和协调方面的差距和潜在机会，以及监管机构和卫生技术评估 (HTA) 机构在利用 RWE 方面的协调一致。

市场参与者展望

服务全球现实世界证据解决方案市场的主要公司包括 Dassault Systemes SE、IBM Corp.、Oracle、PerkinElmer Inc.、Thermo Fisher Scientific Inc. 等。市场参与者透过各种策略（包括併购、合作、合作、融资和新产品发布），为市场成长做出了巨大贡献，以保持市场竞争力。例如，2023 年 8 月，Thermo Fisher Scientific Inc. 收购了 CorEvitas, LLC，专注于常规临床护理中的真实证据收集和使用，这是製药和生物技术客户的高成长细分市场。

2023 年 12 月，BC Platforms 收购了 Medexprim，扩大了为全球生物製药合作伙伴提供安全存取真实临床和影像资料资产的能力。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要发现
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Cegedim Health
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Clinigen Ltd.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Cognizant Technology Solutions Corp.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按组件分類的全球真实世界证据解决方案市场
    • 服务
    • 数据集
      • 不同的数据集
      • 综合数据集
  • 全球真实世界证据解决方案市场（按应用）
    • 药物开发和批准
    • 上市后监督
    • 市场准入报销/涵盖最终用户决策
    • 临床和监管决策
  • 按最终用户分類的全球真实世界证据解决方案市场
    • 製药及医疗器材公司
    • 医疗保健机构
    • 医疗保健支付者
    • 其他（病患和病患权益团体、研究组织和学术界）

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区

第 6 章：公司简介

  • Dassault Systemes S.E.
  • Flatiron Health
  • IBM Corp.
  • ICON plc.
  • India Medtronic Pvt. Ltd.
  • IQVIA, Inc.
  • Optum, Inc.
  • Oracle
  • Parexel International Corp.
  • PerkinElmer Inc.
  • Real Endpoints
  • Saama Technologies, LLC.
  • SAS Institute Inc.
  • Syneos Health
  • Thermo Fisher Scientific Inc.
  • TriNetX LLC
Product Code: OMR2028128

Global Real World Evidence Solutions Market Size, Share & Trends Analysis Report by Component (Services, and Data Sets), by Application (Drug Development and Approvals, Post-Market Surveillance, Market Access Reimbursement/Cover End-User Decision Making, and Clinical and Regulatory Decision-Making), and by End-User (Pharmaceutical & Medical Device Companies, Healthcare Providers, Healthcare Payers, and Others ) Forecast Period (2024-2031)

The global real-world evidence solutions market is anticipated to grow at a CAGR of 12.40% during the forecast period (2024-2031). The market's growth is attributed to the growing demand for healthcare industry is prioritizing patient-centric approaches, aiming for faster and more efficient clinical trials to expedite access to innovative treatments for patients.. For instance, in June 2023, Verana Health launched VeraSite, a subscription-based tool for identifying potential clinical trial sites. The tool allows sponsors and CROs to quickly identify practices with clinical expertise and patient populations, guiding site selection and allowing direct contact with practices of interest.

Segmental Outlook

The global real-world evidence solutions market is segmented by component, application, and end user. Based on the component, the market is sub-segmented into services, and data sets.. Based on the application, the market is sub-segmented intodrug development and approvals, post-market surveillance, market access reimbursement/cover end-user decision making, and clinical and regulatory decision-making.. Furthermore, based on end users, the market is sub-segmented into pharmaceutical & medical device companies, healthcare providers, healthcare payers, and others.. The pharmaceutical and medical device companies' subcategory is expected to capture a significant portion of the market share within the end-user segment. The growth can be attributed to the increasing importance of real world evidence (RWE) studies are increasingly crucial in drug approval, real-world performance assessment, and preventing recalls, aiding in patient benefit identification, regulatory approvals, reimbursement, and increased indications of use.

Oncology Sub-Sub-Segment is Anticipated to Hold a Considerable Share of the Global Real-World Evidence Solutions Market

Among the applications, the oncology sub-sub-segment is expected to hold a considerable share of the global real-world evidence solutions market. The segmental growth is attributed to the growing emphasis for data-driven decision-making in cancer research and treatment, reflecting wider industry trends. Furthermore, the market players are looking for the new product launch to meet the demand for the solutions. . For instance, in May 2023, Flatiron Health expanded into oncology real-world evidence generation. Its Integrated real-world evidence (RWE) Solutions approach allows partners to generate strong RWE and insights. It enables Flatiron to become a 'one-stop-shop' for oncology RWD/E development across the product lifecycle, hence enhancing cancer patient experiences.

Regional Outlook

The global real-world evidence solutions market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia), and the Rest of the World (the Middle East & Africa, and Latin America). Among these, Asia-Pacific is anticipated to hold a prominent share of the market across the globe, owing to the growing number of elderly individuals and the higher occurrence of cancer and chronic illnesses in the region, additionally there has been an increase in demand for healthcare services..

The North American region is Expected to Grow at a Significant CAGR in the global Real-World Evidence Solutions Market

Among all regions, the North American region is anticipated to grow at a considerable CAGR over the forecast period. Regional growth is attributed to the growing availability of high-quality real-world data sources such as wearables, healthcare apps, and electronic health records. . According to the National Institute og Health (gov.), in October 2023, the publication provides an updated review of the global regulatory landscape for leveraging real-world evidence (RWE) in healthcare. It evaluates the availability of frameworks, guidance, data quality, study methods, and procedural guidance in different regions. The review also highlights gaps and potential opportunities for future development and harmonization, as well as the alignment among regulators and health technology assessment (HTA) bodies in utilizing RWE..

Market Players Outlook

The major companies serving the global real-world evidence solutions market include Dassault Systemes S.E., IBM Corp., Oracle, PerkinElmer Inc., Thermo Fisher Scientific Inc., and others. The market players are considerably contributing to the market growth by the adoption of various strategies including mergers and acquisitions, partnerships, collaborations, funding, and new product launches, to stay competitive in the market. For instance, in August 2023, Thermo Fisher Scientific Inc. acquired CorEvitas, LLC, focusing on real-world evidence collection and use in routine clinical care, a high-growth market segment for pharmaceutical and biotechnology customers.

In December 2023, BC Platforms acquired Medexprim, expanding its capability to offer global biopharma partners secure access to real-world clinical and imaging data assets.

The Report Covers:

  • Market value data analysis of 2023 and forecast to 2031.
  • Annualized market revenues ($ million) for each market segment.
  • Country-wise analysis of major geographical regions.
  • Key companies operating in the global real-world evidence solutions market. Based on the availability of data, information related to new product launches, and relevant news is also available in the report.
  • Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
  • Analysis of market-entry and market expansion strategies. Competitive strategies by identifying 'who-stands-where' in the market.

Table of Contents

1.Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1.Research Methods and Tools
  • 1.2.Market Breakdown
    • 1.2.1.By Segments
    • 1.2.2.By Region

2.Market Overview and Insights

  • 2.1.Scope of the Report
  • 2.2.Analyst Insight & Current Market Trends
    • 2.2.1.Key Findings
    • 2.2.2.Recommendations
    • 2.2.3.Conclusion

3.Competitive Landscape

  • 3.1.Key Company Analysis
  • 3.2.Cegedim Health
    • 3.2.1.Overview
    • 3.2.2.Financial Analysis
    • 3.2.3.SWOT Analysis
    • 3.2.4.Recent Developments
  • 3.3.Clinigen Ltd.
    • 3.3.1.Overview
    • 3.3.2.Financial Analysis
    • 3.3.3.SWOT Analysis
    • 3.3.4.Recent Developments
  • 3.4.Cognizant Technology Solutions Corp.
    • 3.4.1.Overview
    • 3.4.2.Financial Analysis
    • 3.4.3.SWOT Analysis
    • 3.4.4.Recent Developments
  • 3.5.Key Strategy Analysis

4.Market Segmentation

  • 4.1.Global Real-World Evidence Solutions Market by Component
    • 4.1.1.Services
    • 4.1.2.Data Sets
      • 4.1.2.1.Disparate Data Sets
      • 4.1.2.2.Integrated Data Sets
  • 4.2.Global Real-World Evidence Solutions Market by Application
    • 4.2.1.Drug Development and Approvals
    • 4.2.2.Post-Market Surveillance
    • 4.2.3.Market Access Reimbursement/Cover End-User Decision Making
    • 4.2.4.Clinical and Regulatory Decision-Making
  • 4.3.Global Real-World Evidence Solutions Market by End-User
    • 4.3.1.Pharmaceutical & Medical Device Companies
    • 4.3.2.Healthcare Providers
    • 4.3.3.Healthcare Payers
    • 4.3.4.Others (Patients and Patient Advocacy Groups, Research Organizations and Academia)

5.Regional Analysis

  • 5.1.North America
    • 5.1.1.United States
    • 5.1.2.Canada
  • 5.2.Europe
    • 5.2.1.UK
    • 5.2.2.Germany
    • 5.2.3.Italy
    • 5.2.4.Spain
    • 5.2.5.France
    • 5.2.6.Rest of Europe
  • 5.3.Asia-Pacific
    • 5.3.1.China
    • 5.3.2.India
    • 5.3.3.Japan
    • 5.3.4.South Korea
    • 5.3.5.Rest of Asia-Pacific
  • 5.4.Rest of the World

6.Company Profiles

  • 6.1.Dassault Systemes S.E.
  • 6.2.Flatiron Health
  • 6.3.IBM Corp.
  • 6.4.ICON plc.
  • 6.5.India Medtronic Pvt. Ltd.
  • 6.6.IQVIA, Inc.
  • 6.7.Optum, Inc.
  • 6.8.Oracle
  • 6.9.Parexel International Corp.
  • 6.10.PerkinElmer Inc.
  • 6.11.Real Endpoints
  • 6.12.Saama Technologies, LLC.
  • 6.13.SAS Institute Inc.
  • 6.14.Syneos Health
  • 6.15.Thermo Fisher Scientific Inc.
  • 6.16.TriNetX LLC

LIST OF TABLES

  • 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ACCESS REIMBURSEMENT/COVER END USER DECISION MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHER END-USERS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 15.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 16.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 17.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 18.NORTH AMERICAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 19.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 20.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 21.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 22.EUROPEAN REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 23.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COUNTRY, 2023-2031 ($ MILLION)
  • 24.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 25.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 26.ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END-USER, 2023-2031 ($ MILLION)
  • 27.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY REGION, 2023-2031 ($ MILLION)
  • 28.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY COMPONENT, 2023-2031 ($ MILLION)
  • 29.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY APPLICATION, 2023-2031 ($ MILLION)
  • 30.REST OF THE WORLD REAL-WORLD EVIDENCE SOLUTIONS MARKET RESEARCH AND ANALYSIS BY END USER, 2023-2031 ($ MILLION)

LIST OF FIGURES

  • 1.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY COMPONENT, 2023 VS 2031 (%)
  • 2.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY SERVICES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 3.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 4.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY DISPARATE DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 5.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS BY INTEGRATED DATA SETS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 6.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY APPLICATION, 2023 VS 2031 (%)
  • 7.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN DRUG DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 8.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN ONCOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 9.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN NEUROLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 10.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN IMMUNOLOGY MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 11.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CARDIOVASCULAR DISEASE MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 12.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN OTHER THERAPEUTIC AREAS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 13.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MEDICAL DEVICE DEVELOPMENT AND APPROVALS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 14.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN POST-MARKET SURVEILLANCE MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 15.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN MARKET ACCESS REIMBURSEMENT/COVERAGE DECISION MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 16.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS IN CLINICAL AND REGULATORY DECISION-MAKING MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 17. GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY END-USER, 2023 VS 2031 (%)
  • 18.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR PHARMACEUTICAL & MEDICAL DEVICE COMPANIES MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 19.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PROVIDERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 20.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR HEALTHCARE PAYERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 21.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS FOR OTHERS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 22.GLOBAL REAL-WORLD EVIDENCE SOLUTIONS MARKET SHARE BY REGION, 2023 VS 2031 (%)
  • 23.US REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 24.CANADA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 25.UK REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 26.FRANCE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 27.GERMANY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 28.ITALY REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 29.SPAIN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 30.REST OF EUROPE REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 31.INDIA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 32.CHINA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 33.JAPAN REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 34.SOUTH KOREA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 35.REST OF ASIA-PACIFIC REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 36.LATIN AMERICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)
  • 37.THE MIDDLE EAST & AFRICA REAL-WORLD EVIDENCE SOLUTIONS MARKET SIZE, 2023-2031 ($ MILLION)